Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 5 studies | 31% ± 13% | |
ciliated cell | 3 studies | 24% ± 6% | |
endothelial cell | 3 studies | 24% ± 5% | |
erythrocyte | 3 studies | 25% ± 6% |
Insufficient scRNA-seq data for expression of CDC34 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2929.71 | 1445 / 1445 | 100% | 57.47 | 183 / 183 |
liver | 100% | 3286.68 | 226 / 226 | 100% | 114.16 | 406 / 406 |
pancreas | 100% | 2173.62 | 328 / 328 | 100% | 88.19 | 178 / 178 |
brain | 100% | 3033.67 | 2638 / 2642 | 100% | 135.89 | 705 / 705 |
thymus | 100% | 2105.87 | 652 / 653 | 100% | 93.69 | 605 / 605 |
skin | 100% | 2951.13 | 1808 / 1809 | 100% | 111.54 | 471 / 472 |
stomach | 100% | 2144.66 | 359 / 359 | 100% | 97.55 | 285 / 286 |
adrenal gland | 100% | 2426.60 | 258 / 258 | 100% | 112.02 | 229 / 230 |
uterus | 100% | 2703.26 | 170 / 170 | 100% | 106.73 | 457 / 459 |
ovary | 100% | 2437.17 | 180 / 180 | 100% | 74.84 | 428 / 430 |
intestine | 100% | 3225.90 | 966 / 966 | 99% | 120.59 | 524 / 527 |
kidney | 100% | 2065.46 | 89 / 89 | 99% | 67.96 | 895 / 901 |
prostate | 100% | 2866.04 | 245 / 245 | 99% | 94.15 | 498 / 502 |
bladder | 100% | 3059.29 | 21 / 21 | 99% | 123.49 | 499 / 504 |
lung | 100% | 2383.03 | 577 / 578 | 99% | 80.04 | 1144 / 1155 |
breast | 100% | 2425.39 | 459 / 459 | 99% | 74.70 | 1102 / 1118 |
eye | 0% | 0 | 0 / 0 | 100% | 96.94 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 90.08 | 29 / 29 |
muscle | 100% | 3950.51 | 803 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 5645.66 | 929 / 929 | 0% | 0 | 0 / 0 |
spleen | 100% | 2318.37 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 78.32 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 138.37 | 1 / 1 |
blood vessel | 100% | 2369.22 | 1334 / 1335 | 0% | 0 | 0 / 0 |
adipose | 100% | 2327.00 | 1203 / 1204 | 0% | 0 | 0 / 0 |
heart | 100% | 3075.06 | 859 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0043525 | Biological process | positive regulation of neuron apoptotic process |
GO_0035458 | Biological process | cellular response to interferon-beta |
GO_0070936 | Biological process | protein K48-linked ubiquitination |
GO_0036211 | Biological process | protein modification process |
GO_0006270 | Biological process | DNA replication initiation |
GO_0090261 | Biological process | positive regulation of inclusion body assembly |
GO_0043951 | Biological process | negative regulation of cAMP-mediated signaling |
GO_0070848 | Biological process | response to growth factor |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0000082 | Biological process | G1/S transition of mitotic cell cycle |
GO_0016607 | Cellular component | nuclear speck |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005634 | Cellular component | nucleus |
GO_0005524 | Molecular function | ATP binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0061631 | Molecular function | ubiquitin conjugating enzyme activity |
GO_0005515 | Molecular function | protein binding |
Gene name | CDC34 |
Protein name | Ubiquitin-conjugating enzyme E2 R1 (EC 2.3.2.23) ((E3-independent) E2 ubiquitin-conjugating enzyme R1) (EC 2.3.2.24) (E2 ubiquitin-conjugating enzyme R1) (Ubiquitin-conjugating enzyme E2-32 kDa complementing) (Ubiquitin-conjugating enzyme E2-CDC34) (Ubiquitin-protein ligase R1) Cell division cycle 34, ubiqiutin conjugating enzyme |
Synonyms | UBE2R1 UBCH3 |
Description | FUNCTION: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys-48'-linked polyubiquitination . Cooperates with the E2 UBCH5C and the SCF(FBXW11) E3 ligase complex for the polyubiquitination of NFKBIA leading to its subsequent proteasomal degradation. Performs ubiquitin chain elongation building ubiquitin chains from the UBE2D3-primed NFKBIA-linked ubiquitin. UBE2D3 acts as an initiator E2, priming the phosphorylated NFKBIA target at positions 'Lys-21' and/or 'Lys-22' with a monoubiquitin. Cooperates with the SCF(SKP2) E3 ligase complex to regulate cell proliferation through ubiquitination and degradation of MYBL2 and KIP1. Involved in ubiquitin conjugation and degradation of CREM isoform ICERIIgamma and ATF15 resulting in abrogation of ICERIIgamma- and ATF5-mediated repression of cAMP-induced transcription during both meiotic and mitotic cell cycles. Involved in the regulation of the cell cycle G2/M phase through its targeting of the WEE1 kinase for ubiquitination and degradation. Also involved in the degradation of beta-catenin. Is target of human herpes virus 1 protein ICP0, leading to ICP0-dependent dynamic interaction with proteasomes . . |
Accessions | ENST00000586283.6 U3KQP9 U3KPV8 ENST00000607527.5 ENST00000606065.3 P49427 ENST00000215574.9 U3KQ77 |